Skip to Content
Merck
CN
  • One-year safety and efficacy results of a hydrogel inlay to improve near vision in patients with emmetropic presbyopia.

One-year safety and efficacy results of a hydrogel inlay to improve near vision in patients with emmetropic presbyopia.

Journal of refractive surgery (Thorofare, N.J. : 1995) (2013-03-01)
Enrique Barragan Garza, Sandra Gomez, Arturo Chayet, Jon Dishler
ABSTRACT

To conduct a feasibility study of the safety and efficacy of a corneal contouring inlay as a treatment for emmetropic presbyopia. The Raindrop corneal inlay (ReVision Optics, Inc., Lake Forest, CA) was implanted on the corneal stromal bed beneath a keratotomy flap in 20 nondominant eyes of 20 patients. The implant is designed to cause a change in the curvature of the overlying cornea, with a subsequent multifocal change in refractive power. Efficacy outcome was defined as at least 75% of eyes with uncorrected near visual acuity of 0.3 logMAR (20/40 Snellen) or better at 6 months. Main safety outcomes were retention of preoperative best-corrected distance visual acuity and reports of adverse events. Other outcome measures included contrast sensitivity; near, intermediate, and distance visual acuities; patient satisfaction; spectacle use; and complications. All implanted eyes achieved uncorrected near visual acuity of 0.3 logMAR (20/40 Snellen) or better by the 1-week postoperative examination and remained so throughout the 1-year follow-up period, also averaging less than 0.1 logMAR (20/25 Snellen) monocularly and binocularly throughout that period. Mean binocular uncorrected distance visual acuity remained within 0.02 logMAR of the preoperative mean throughout the study. One patient who was dissatisfied with the resulting vision underwent explantation. At 1 year, 16 of 19 patients seldom or never wore glasses and all 19 were satisfied or very satisfied with their overall vision. The hydrogel corneal inlay improved uncorrected near and intermediate visual acuity in patients with emmetropic presbyopia, with high patient satisfaction and little effect on distance visual acuity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Poly(ethylene glycol) dimethacrylate, average Mn 2000, contains ~1000 ppm MeHQ as stabilizer
Sigma-Aldrich
Poly(ethylene glycol) dimethacrylate, average Mn 550, contains 80-120 ppm MEHQ as inhibitor, 270-330 ppm BHT as inhibitor
Sigma-Aldrich
Poly(ethylene glycol) dimethacrylate, average Mn 10,000, contains MEHQ as inhibitor
Sigma-Aldrich
Poly(ethylene glycol) dimethacrylate, average Mn 20,000, contains MEHQ as inhibitor
Sigma-Aldrich
Poly(ethylene glycol) dimethacrylate, average Mn 6,000, contains 1000 ppm 4-methoxyphenol as inhibitor
Sigma-Aldrich
Poly(ethylene glycol) dimethacrylate, average Mn 750, contains 900-1100 ppm MEHQ as inhibitor